Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Hims & Hers Health, Inc. Class A Common Stock
(NY:
HIMS
)
37.17
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EDT, Jul 15, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Hims & Hers Health, Inc. Class A Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
55
56
Next >
What's Going On With Hims & Hers Shares
↗
April 17, 2026
Shares of Hims & Hers Health Inc. (NASDAQ: HIMS) are rising Friday on the momentum from U.S. drug regulators easing restrictions on peptides.
Via
Benzinga
Stock Market Today, April 16: Hims & Hers Health Jumps on FDA Review of Compounded Peptide Therapies
↗
April 16, 2026
On April 16, 2026, investors monitored an FDA peptide review that could be a boost to Hims & Hers Health.
Via
The Motley Fool
Topics
Stocks
Q4 Earnings Outperformers: Hims & Hers Health (NYSE:HIMS) And The Rest Of The Healthcare Technology Stocks
April 15, 2026
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the healthcare technology stocks, including Hims & Hers Health (NYSE:HIMS) and its peer...
Via
StockStory
Hims & Hers to Announce First Quarter 2026 Financial Results on May 11, 2026
April 13, 2026
From
Hims & Hers
Via
Business Wire
Did Hims & Hers Just Become an AI Company?
↗
April 10, 2026
Artificial intelligence could be a big differentiator for Hims & Hers.
Via
The Motley Fool
Topics
Artificial Intelligence
2 Profitable Stocks with Exciting Potential and 1 We Ignore
April 10, 2026
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ...
Via
StockStory
3 Sectors to Buy While They're Down and 1 to Walk Away From
↗
April 07, 2026
When the S&P 500 was flirting with 7,000 back in January, everyone wanted in. Now, with the index 400 to 500 points lower, the mood has flipped to fear. That disconnect between price and psychology is...
Via
MarketBeat
Topics
Stocks
Hims & Hers Health Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Hims & Hers Health, Inc. - HIMS
April 03, 2026
From
Kahn Swick & Foti, LLC
Via
Business Wire
Should You Buy Hims Stock Today?
↗
April 02, 2026
The healthcare industry is ripe for disruption, and Hims is making early progress in this effort.
Via
The Motley Fool
Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know
April 02, 2026
What Happened? A number of stocks fell in the afternoon session after reports revealed that the US may impose up to 100% tariffs on imports of branded and pa...
Via
StockStory
Topics
Government
Stocks
World Trade
HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation with the Schall Law Firm
April 01, 2026
From
Schall Law
Via
GlobeNewswire
Enovis, Neogen, Humana, LifeStance Health Group, and Hims & Hers Health Stocks Trade Down, What You Need To Know
March 27, 2026
What Happened? A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones Industrial Average fell sharply as in...
Via
StockStory
Topics
Government
Stocks
2 Mooning Stocks on Our Buy List and 1 Facing Challenges
March 27, 2026
The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, u...
Via
StockStory
Topics
Initial Public Offering
What's Happening With Novo Nordisk Stock Today?
↗
March 26, 2026
Novo Nordisk A/S (NYSE:NVO) shares are moving higher on Thursday. Hims & Hers Health Inc (NYSE:HIMS) announced it will begin offering several of the Novo's FDA‑approved GLP‑1 medications, including the...
Via
Benzinga
Novo Nordisk’s FDA-Approved GLP-1s Now Available With Hims & Hers
March 26, 2026
From
Hims & Hers
Via
Business Wire
Surging Oil Prices Spark Market Jitters
↗
March 25, 2026
The Motley Fool's Hidden Gems team discusses some historical disruptions in the energy market, how trends in semiconductors are reshaping the S&P 500, and why Hims & Hers stock is soaring.
Via
The Motley Fool
Topics
Artificial Intelligence
Economy
Stocks
HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation with the Schall Law Firm
March 25, 2026
From
Schall Law
Via
GlobeNewswire
2 Healthcare Stocks to Target This Week and 1 That Underwhelm
March 23, 2026
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advanceme...
Via
StockStory
This Hims & Hers Move Could Destroy Competitors
↗
March 21, 2026
The Wegovy pill could change Hims & Hers' growth in 2026.
Via
The Motley Fool
Down Near Its 5-Year Low, Is Novo Nordisk Stock Too Cheap to Pass Up?
↗
March 20, 2026
The healthcare stock has lost more than half of its value in the past year.
Via
The Motley Fool
1 Growth Stock with All-Star Potential and 2 That Underwhelm
March 19, 2026
Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market va...
Via
StockStory
Hims & Hers Opens Waitlist For $149 Branded Wegovy And Ozempic Via Novo Nordisk Deal
↗
March 18, 2026
Hims & Hers Health, Inc. (NYSE:HIMS) trended on Wednesday after the company outlined an expanded weight-management push tied to
Via
Benzinga
Hims & Hers (HIMS) 2026 Deep Dive: The $1.15B Eucalyptus Deal and the Branded Pivot
March 18, 2026
As of March 18, 2026, Hims & Hers Health (NYSE: HIMS) has reclaimed its position as the primary protagonist in the direct-to-consumer (DTC) healthcare narrative. Following a turbulent start to the year...
Via
Finterra
Topics
Intellectual Property
Hims & Hers Opens Up Pre-Launch Waitlist For Ozempic And Wegovy Following Partnership With Novo Nordisk
↗
March 18, 2026
The company stated that people who sign up for the waitlist will gain priority access to the official debut of Ozempic and Wegovy on the telehealth company’s platform.
Via
Stocktwits
Top 2 S&P 500 Stocks to Watch This Week After Hims & Hers Stock's Surprise Move
↗
March 17, 2026
These companies are benefiting from a tidal wave of demand for new weight-loss drugs.
Via
The Motley Fool
Topics
Stocks
Hims & Hers Health Stock Slips After Surging 50% In A Month
↗
March 16, 2026
Hims & Hers Health Inc (NYSE: HIMS) shares are pulling back Monday morning, giving back a portion of last week's sharp rally.
Via
Benzinga
Why the Novo Nordisk and Hims & Hers Deal Is a Win for Both Stocks
↗
March 16, 2026
The drama and uncertainty around Novo Nordisk and Hims & Hers Health might finally be ending.
Via
The Motley Fool
MarketBeat Week in Review – 03/09 - 03/13
↗
March 14, 2026
Despite continued volatility, stocks have stayed resilient as investors navigate the fog of war. The story is largely about oil. When the price of crude oil goes up, stocks go down and vice versa....
Via
MarketBeat
The Great Pivot: How the Novo Nordisk Deal Transformed Hims & Hers (HIMS) into a Healthcare Powerhouse
March 13, 2026
As of March 13, 2026, the healthcare landscape has witnessed one of the most significant pivots in the history of digital health. Hims & Hers Health, Inc. (NYSE: HIMS) has officially transitioned from...
Via
Finterra
Topics
Economy
Stock Market Today, March 12: Hims and Hers Health Drops After Rally Sparks Profit Taking
↗
March 12, 2026
On March 12, 2026, investors weighed profit-taking against a high-stakes pivot toward branded obesity drugs and telehealth growth.
Via
The Motley Fool
Topics
Intellectual Property
Stocks
< Previous
1
2
3
4
5
6
7
8
9
...
55
56
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.